The effect of rituximab on vaccine responses in patients with immune thrombocytopenia.

B-cell depletion may impair vaccine responses and increase infection risk in patients with immune thrombocytopenia (ITP). We investigated the effects of rituximab on antibody and cellular responses to Streptococcus pneumoniae polysaccharide and Haemophilus influenzae type b (Hib) vaccines in ITP patients. Of 60 patients in the main trial, 24 patients received both vaccines 6 months after rituximab (n = 17) or placebo (n = 7). Among 20 evaluable patients, 3 of 14 (21%) in the rituximab group and 4 of 6 (67%) in the placebo group achieved a fourfold increase in anti-pneumococcal antibodies (P = .12). For anti-Hib antibodies, 4 of 14 (29%) and 5 of 6 (83%), respectively, achieved a fourfold increase (P < .05). Fewer patients in the rituximab group demonstrated Hib killing (2 of 14 [14%], 5 of 6 [83%], P < .05). Three of 14 rituximab-treated patients failed to respond to vaccines by any criteria. After vaccinations, preplasma cell blasts and interferon-γ-secreting T cells were reduced in rituximab-treated patients. Antibody responses were impaired for at least 6 months after rituximab. Cellular immunity was reduced in parallel with depleted B-cell pools. These findings have implications for the timing of vaccinations and the mechanism of infection after rituximab in ITP patients.

[1]  W. Xu,et al.  Evaluation of 2009 pandemic H1N1 influenza vaccination in adults with lymphoid malignancies receiving chemotherapy or following autologous stem cell transplant , 2013, Leukemia & lymphoma.

[2]  A. Jawad,et al.  Rituximab-Treated Patients Have a Poor Response to Influenza Vaccination , 2012, Journal of Clinical Immunology.

[3]  E. Cesarman,et al.  Platelet‐associated antibodies, cellular immunity and FCGR3a genotype influence the response to rituximab in immune thrombocytopenia , 2012, British journal of haematology.

[4]  E. Neufeld,et al.  Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia. , 2012, Blood.

[5]  M. Ulanova,et al.  Risk of Invasive Haemophilus influenzae Type b (Hib) Disease in Adults with Secondary Immunodeficiency in the Post-Hib Vaccine Era , 2012, Clinical and Vaccine Immunology.

[6]  C. Combescure,et al.  A prospective study of the factors shaping antibody responses to the AS03-adjuvanted influenza A/H1N1 vaccine in cancer outpatients. , 2012, The oncologist.

[7]  D. Cook,et al.  A pilot randomized trial of adjuvant rituximab or placebo for nonsplenectomized patients with immune thrombocytopenia. , 2012, Blood.

[8]  A. Tierens,et al.  Rituximab blocks protective serologic response to influenza A (H1N1) 2009 vaccination in lymphoma patients during or within 6 months after treatment. , 2011, Blood.

[9]  H. Ochs,et al.  Effect of rituximab on human in vivo antibody immune responses. , 2011, The Journal of allergy and clinical immunology.

[10]  I. Rafi,et al.  Review of guidelines for the prevention and treatment of infection in patients with an absent or dysfunctional spleen: Prepared on behalf of the British Committee for Standards in Haematology by a Working Party of the Haemato‐Oncology Task Force , 2011, British journal of haematology.

[11]  C. Combescure,et al.  Impact of synthetic and biologic disease-modifying antirheumatic drugs on antibody responses to the AS03-adjuvanted pandemic influenza vaccine: a prospective, open-label, parallel-cohort, single-center study. , 2011, Arthritis and rheumatism.

[12]  M. Crowther,et al.  The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. , 2011, Blood.

[13]  J. Ioannidis,et al.  Vaccination in adult patients with auto-immune inflammatory rheumatic diseases: a systematic literature review for the European League Against Rheumatism evidence-based recommendations for vaccination in adult patients with auto-immune inflammatory rheumatic diseases. , 2011, Autoimmunity reviews.

[14]  P. Armand,et al.  Seroprotective titers against 2009 H1N1 influenza A virus after vaccination in allogeneic hematopoietic stem cell transplantation recipients. , 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[15]  H. Mackay,et al.  Evaluation of pandemic H1N1 (2009) influenza vaccine in adults with solid tumor and hematological malignancies on active systemic treatment. , 2011, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[16]  E. Mendelson,et al.  The cellular immune response to influenza vaccination is preserved in rheumatoid arthritis patients treated with rituximab. , 2011, Vaccine.

[17]  K. Rezvani,et al.  Repeated vaccination is required to optimize seroprotection against H1N1 in the immunocompromised host , 2011, Haematologica.

[18]  B. Kramer,et al.  American Society of Clinical Oncology provisional clinical opinion: chronic hepatitis B virus infection screening in patients receiving cytotoxic chemotherapy for treatment of malignant diseases. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  M. Bokarewa,et al.  Vaccination response to protein and carbohydrate antigens in patients with rheumatoid arthritis after rituximab treatment , 2010, Arthritis research & therapy.

[20]  D. Arnold,et al.  The effect of rituximab on humoral and cell mediated immunity and infection in the treatment of autoimmune diseases , 2010, British journal of haematology.

[21]  J. Bussel,et al.  The Long-term Impact of Rituximab for Childhood Immune Thrombocytopenia , 2010, Current rheumatology reports.

[22]  Shou-Dong Lee,et al.  Hepatitis B virus reactivation after 23 months of rituximab-based chemotherapy in an HBsAg-negative, anti-HBs-positive patient with follicular lymphoma. , 2010, Journal of the Chinese Medical Association : JCMA.

[23]  D. Snider,et al.  Stimulation of anti-polio and anti-HSV IgA pre-plasma cell response in blood following parenteral immunization with tetanus-diphtheria vaccine. , 2010, Vaccine.

[24]  C. Teng,et al.  Hepatitis B reactivation induced by Rituximab maintenance therapy for lymphoma , 2010, Annals of Hematology.

[25]  A. Riis,et al.  Risk for Hospital Contact With Infection in Patients With Splenectomy , 2009, Annals of Internal Medicine.

[26]  D. West,et al.  Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a Review from the Research on Adverse Drug Events and Reports (RADAR) Project. , 2009, The Lancet. Oncology.

[27]  David Green,et al.  Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. , 2009, Blood.

[28]  R. Ahmed,et al.  Requirement of B Cells for Generating CD4+ T Cell Memory1 , 2009, The Journal of Immunology.

[29]  S. Amadori,et al.  Analysis of regulatory T-cell changes in patients with idiopathic thrombocytopenic purpura receiving B cell-depleting therapy with rituximab. , 2008, Blood.

[30]  E. Angelucci,et al.  Hepatitis B virus-related liver disease in isolated anti-hepatitis B-core positive lymphoma patients receiving chemo- or chemo-immune therapy , 2008, Haematologica.

[31]  J. Ablin,et al.  Vaccination against influenza in patients with rheumatoid arthritis: the effect of rituximab on the humoral response , 2007, Annals of the rheumatic diseases.

[32]  R. Sorensen,et al.  Assessment and clinical interpretation of polysaccharide antibody responses. , 2007, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[33]  S. Amadori,et al.  Response to B-cell depleting therapy with rituximab reverts the abnormalities of T-cell subsets in patients with idiopathic thrombocytopenic purpura. , 2007, Blood.

[34]  F. Dentali,et al.  Systematic Review: Efficacy and Safety of Rituximab for Adults with Idiopathic Thrombocytopenic Purpura , 2007, Annals of Internal Medicine.

[35]  Stanley B. Cohen,et al.  Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. , 2006, Arthritis and rheumatism.

[36]  S. Romero-Steiner,et al.  Immunologic Response to Haemophilus influenzae Type b (Hib) Conjugate Vaccine and Risk Factors for Carriage among Hib Carriers and Noncarriers in Southwestern Alaska , 2006, Clinical and Vaccine Immunology.

[37]  S. Vesely,et al.  Splenectomy for adult patients with idiopathic thrombocytopenic purpura: a systematic review to assess long-term platelet count responses, prediction of response, and surgical complications. , 2004, Blood.

[38]  P. Emery,et al.  Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. , 2004, The New England journal of medicine.

[39]  S. Horning,et al.  Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma. , 2004, Blood.

[40]  S. Romero-Steiner,et al.  Measurement of Serum Bactericidal Activity Specific for Haemophilus influenzae Type b by Using a Chromogenic and Fluorescent Metabolic Indicator , 2004, Clinical Diagnostic Laboratory Immunology.

[41]  J. Bussel,et al.  Long term follow‐up after splenectomy performed for immune thrombocytopenic purpura (ITP) , 2003, American journal of hematology.

[42]  Antonio Lanzavecchia,et al.  Maintenance of Serological Memory by Polyclonal Activation of Human Memory B Cells , 2002, Science.

[43]  I. Lavi,et al.  Risk of infection and death among post-splenectomy patients. , 2001, The Journal of infection.

[44]  G. Lau,et al.  Hepatitis B virus (HBV) reactivation after cytotoxic or immunosuppressive therapy — pathogenesis and management , 2001, Reviews in medical virology.

[45]  R. Westendorp,et al.  Morbidity and mortality in adults with idiopathic thrombocytopenic purpura. , 2001, Blood.

[46]  A. Schuchat,et al.  Age-Dependent Neisseria meningitidis Serogroup C Class-Specific Antibody Concentrations and Bactericidal Titers in Sera from Young Children from Montana Immunized with a Licensed Polysaccharide Vaccine , 1998, Infection and Immunity.

[47]  P. Ejstrud,et al.  Antibody levels against Streptococcus pneumoniae and Haemophilus influenzae type b in a population of splenectomized individuals with varying vaccination status , 1997, Epidemiology and Infection.

[48]  D. Granoff,et al.  Variability in the Functional Activity of Vaccine-Induced Antibody to Haemophilus influenzae Type b , 1990, Pediatric Research.

[49]  P. Anderson.  The protective level of serum antibodies to the capsular polysaccharide of Haemophilus influenzae type b. , 1984, The Journal of infectious diseases.